4//SEC Filing
Thomas Steffen 4
Accession 0001731122-25-000837
CIK 0001314052other
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 5:30 PM ET
Size
8.9 KB
Accession
0001731122-25-000837
Insider Transaction Report
Form 4
Thomas Steffen
Director
Transactions
- Tax Payment
Common stock
2025-06-05$7.75/sh−11,349$87,955→ 43,651 total - Exercise/Conversion
Common stock
2025-06-05$1.76/sh+50,000$88,000→ 55,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-05−50,000→ 0 totalExercise: $1.76Exp: 2025-06-15→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan.
- [F2]The options vested in three equal annual installments beginning on June 15, 2016
Documents
Issuer
ANAVEX LIFE SCIENCES CORP.
CIK 0001314052
Entity typeother
Related Parties
1- filerCIK 0001646396
Filing Metadata
- Form type
- 4
- Filed
- Jun 8, 8:00 PM ET
- Accepted
- Jun 9, 5:30 PM ET
- Size
- 8.9 KB